| Basic information all primary antibodies complete? |
100% |
1.00 |
1.00–1.00 |
16 |
| Any validation information present (at least one antibody)? |
75% |
0.50 |
0.13–0.87 |
16 |
| All primary antibodies validated? |
94% |
IND |
/ |
16 |
|
|
|
|
|
| If validated: |
|
|
|
|
| Reference to validation by antibody supplier? |
100% |
IND |
/ |
8 |
| Reference to validation in the literature? |
88% |
0.75 |
0.31–1.00 |
8 |
| Reference to validation information in database? |
100% |
IND |
/ |
8 |
| Antibody validation carried out by authors of article? |
63% |
−0.20 |
−0.49–0.088 |
8 |
|
|
|
|
|
| If carried out by authors, which method? |
|
|
|
|
| Molecular weight similar to target (in WB)? |
83% |
0.57 |
−0.12–1.00 |
6 |
| Spatial localization? |
100% |
1.00 |
1.00–1.00 |
6 |
| Pre-adsorption/blocking peptide? |
100% |
1.00 |
1.00–1.00 |
6 |
| Using secondary antibody without primary? |
100% |
IND |
/ |
6 |
| One of the five pillars? |
100% |
1.00 |
1.00–1.00 |
6 |
| Positive control? |
67% |
0.33 |
−0.23–0.90 |
6 |
| Negative control? |
67% |
IND |
/ |
6 |
| Other validation method? |
50% |
0.00 |
−0.75–0.75 |
6 |
|
| Question |
ICC |
95% CI |
N |
| How many antibodies were used? |
0.995 |
0.986–0.998 |
15 |
| How many antibodies were validated? |
0.684 |
0.263–0.886 |
14 |
| Percentage of validated antibodies? |
0.663 |
0.226–0.878 |
14 |
